Shenogen Pharma Group, Chemizon sign drug discovery collaboration agreement
October 31, 2015
"The fact that it was not a general decline gives further credence to the idea that it was something very specific commonly affecting this group of women," said lead study author Nancy Krieger, Ph.D. "It looks like the most logical thing was a change in the administration of hormone therapy. The rates didn't decline among white women living in less affluent countries or black women in rich or poor countries."
Krieger is a professor in the department of society, human development and health at the Harvard School of Public Health.
To Susan Brown, director of health education for Susan G. Komen for the Cure, these studies underline an important lesson. "The WHI study reminded us of the importance of having enough evidence. The idea that hormone therapy prevented cardiovascular problems relied on only one rigorous scientific study. If your doctor prescribes a treatment, you might want to ask, what do studies show, what is the evidence? Physicians should be prepared to answer these questions."
With any prescribed treatment, there are risks and benefits, Brown said. "To really make an informed choice, it's important to understand the risks."
Source: American Journal of Public Health